Umbilical Cord Blood as a Source of Less Differentiated T Cells to Produce CD123 CAR-T Cells
Blandine Caël, Jeanne Galaine, Isabelle Bardey, Chrystel Marton, Maxime Fredon, Sabeha Biichlé, Margaux Poussard, Yann Godet, Fanny Angelot‐Delettre, Christophe Barisien, Christophe Bésiers, Olivier Adotévi, Fabienne Pouthier, Francine Garnache‐Ottou, Elodie Bôle‐Richard
Abstract
Chimeric Antigen Receptor (CAR) therapy has led to great successes in patients with leukemia and lymphoma. Umbilical Cord Blood (UCB), stored in UCB banks, is an attractive source of T cells for CAR-T production. We used a third generation CD123 CAR-T (CD28/4-1BB), which was previously developed using an adult's Peripheral Blood (PB), to test the ability of obtaining CD123 CAR-T from fresh or cryopreserved UCB. We obtained a cell product with a high and stable transduction efficacy, and a poorly differentiated phenotype of CAR-T cells, while retaining high cytotoxic functions in vitro and in vivo. Moreover, CAR-T produced from cryopreserved UCB are as functional as CAR-T produced from fresh UCB. Overall, these data pave the way for the clinical development of UCB-derived CAR-T. UCB CAR-T could be transferred in an autologous manner (after an UCB transplant) to reduce post-transplant relapses, or in an allogeneic setting, thanks to fewer HLA restrictions which ease the requirements for a match between the donor and recipient.